TY - JOUR
T1 - Inhibition of Nocturnal Gastric Secretion in Normal Human Volunteers by Misoprostol
T2 - A Synthetic Prostaglandin E1 Methyl Ester Analog
AU - Akdamar, K.
AU - Agrawal, N.
AU - Ertan, Atilla
PY - 1982/1/1
Y1 - 1982/1/1
N2 - Misoprostol (SC-29333) is a synthetic prostaglandin E1 analog that has been found to be a potent inhibitor of gastric secretion in animals. Nocturnal gastric antisecretory activity of misoprostol, in tablet form, was studied in 16 adult volunteers, under basal conditions. The study was a randomized, double-blind, cross-over, comparison of placebo, and three graded doses of misoprostol (50, 100, and 200 μg). Misoprostol exhibited a statistically significant inhibition of total acid output only at the 200 μg dose and this inhibition was maintained for 3 h postadministration of the drug. The antisecretory effects of misoprostol were characterized by suppression of H+ ion but not of the volume of gastric secretion. No untoward effects were noted in the volunteers. As a consequence of the gastric antisecretory effects, the present studies indicate that misoprostol is a promising therapeutic agent for the treatment of peptic ulcer.
AB - Misoprostol (SC-29333) is a synthetic prostaglandin E1 analog that has been found to be a potent inhibitor of gastric secretion in animals. Nocturnal gastric antisecretory activity of misoprostol, in tablet form, was studied in 16 adult volunteers, under basal conditions. The study was a randomized, double-blind, cross-over, comparison of placebo, and three graded doses of misoprostol (50, 100, and 200 μg). Misoprostol exhibited a statistically significant inhibition of total acid output only at the 200 μg dose and this inhibition was maintained for 3 h postadministration of the drug. The antisecretory effects of misoprostol were characterized by suppression of H+ ion but not of the volume of gastric secretion. No untoward effects were noted in the volunteers. As a consequence of the gastric antisecretory effects, the present studies indicate that misoprostol is a promising therapeutic agent for the treatment of peptic ulcer.
UR - http://www.scopus.com/inward/record.url?scp=0020420911&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020420911&partnerID=8YFLogxK
U2 - 10.1111/j.1572-0241.1982.tb05906.x
DO - 10.1111/j.1572-0241.1982.tb05906.x
M3 - Article
C2 - 6816064
AN - SCOPUS:0020420911
SN - 0002-9270
VL - 77
SP - 902
EP - 904
JO - The American Journal of Gastroenterology
JF - The American Journal of Gastroenterology
IS - 12
ER -